Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00376532 · ClinicalTrials.gov registry record
Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 63
- Enrollment target
NCT00376532: Completed study, sponsored by Thomas Jefferson University.
NCT00376532 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00376532 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular tachycardia or fibrillation in patients who have implantable cardioverter defibrillator devices.
Primary Outcome
Serum MMP-2 levels determined by Aushon Biosystems Searchlight® Protein Array Analysis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-09 |
What the finished NCT00376532 record still lists
NCT00376532 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00376532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00376532 about?
NCT00376532 is a clinical study titled "Extracellular Matrix Marker of Arrhythmia Risk (EMMA)". Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular tachycardia or fibrillation in patients who have implantable cardioverter defibrillator devices.
What is the current status of trial NCT00376532?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2006-09. Estimated completion is 2008-09.
Who is sponsoring clinical trial NCT00376532?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia